Effectiveness and safety of mono-anlotinib mono therapy or in combination with chemotherapy in platinum-resistant recurrent ovarian cancer: a single-center retrospective study.

Objective: To evaluate the clinical efficacy of mono-anlotinib therapy by itself or in combination with chemotherapy in platinum-resistant recurrent ovarian cancer (PROC).

Methods: The clinical data of 35 patients with platinum-resistant recurrent ovarian cancer admitted to the First Affiliated Hospital of Anhui Medical University from March 2019 to July 2020 were retrospectively analyzed. All the patients received anlotinib mono- or combined chemotherapy. The effectiveness and adverse events (AEs) were analyzed by RECIST1.1 and CTCAE5.0.

Results: In the 35 patients, the median follow-up was 9.80 (95% CI: 3.83-15.77) months. The median progression free survival (mPFS) achieved 6.50 (95% CI: 2.02-10.98) months, the objective response rate (ORR) achieved 17.14%, and disease control rate (DCR) achieved 60.00%. ORR and DCR were 12.50% and 25.0% for monotherapy, 18.52% and 70.37% for combined chemotherapy. The PFS of combined chemotherapy was longer than that of monotherapy (log-rank P = 0.003). thirty-four patients (97.14%) were in a third-line therapy or above, and their ORR and DCR were 14.71% and 58.82%, respectively. Two patients discontinued treatment because of intolerable AEs. No cases of grade 4-5 AEs have been reported.

Conclusion: Anlotinib had promising effectiveness and tolerable safety in patients with PROC, even in patients who accepted anlotinib as a third-line or above therapy or with a history of other antiangiogenic drugs.